Adherex Eniluracil Phase III To Start Mid ’07; Firm Outlines Fixes For Failed GSK Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Adherex believes it has identified ways to optimize its chemotherapy enhancing agent eniluracil for use in combination with 5-fluorouracil
You may also be interested in...
Stock Watch: Pharma Castoffs Sink Without A Trace … Eventually
When a small biotech company acquires a failed drug from big pharma and plans to repeat the clinical studies expecting a positive result, is that not a definition of insanity?
Adherex Licenses GSK’s Eniluracil, Estimates Oncologic’s Potential At $1 Bil.
Adherex gains rights to GlaxoSmithKline's oncology agent eniluracil in exchange for a GSK option on Adherex' lead biotechnology oncologic ADH-1 under a combined licensing agreement, announced July 15
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011